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Abstract
Introduction: Hemodialysis (HD) and hemodiafiltration clear only with a low efficiency the plasma from interleukin-6 and p-
cresol, two protein-bound uremic toxins associated with high cardiovascular risk in end stage renal disease. HFR Supra is a
double-chamber hemodiafiltration system in which the ultrafiltrate returns to the patient after its regeneration through a
resin cartridge that binds hydrophobic and protein-bound solutes. In the present study, we evaluated whether the HFR
cartridge can also bind total p-cresol and IL-6 and remove them from the ultrafiltrate.
Methods: We compared the levels of IL-6 and p-cresol in ultrafiltrate samples collected at the inlet (UFin) and at the outlet
(UFout) of the cartridge at the start or at the end of a 240 min HFR session in 12 inflamed chronic HD patients. The pro-
inflammatory activity of the ultrafiltrate samples was also determined by evaluating the changes that they induced in IL-6
mRNA expression and protein release in peripheral blood mononuclear cells from 12 healthy volunteers. IL-6 and p-cresol
circulating levels were also assessed in peripheral plasma blood samples collected before and after HFR and, for comparison,
a control HD.
Results: p-Cresol and IL-6 were lower in UFout than in UFin both at the start and at the end of the HFR session, suggesting
that they were retained by the cartridge. IL-6 mRNA expression and release were lower in PBMC incubated with UFout
collected at the end than with UFin collected at the start of HFR, suggesting that passage through the cartridge reduced UF
pro-inflammatory activity. Plasma total p-cresol decreased by about 53% after HFR, and 37% after HD. IL-6 circulating values
were unmodified by either these dialysis procedures.
Conclusions: This study shows that the HFR-Supra cartridge retains total p-cresol and IL-6 in the ultrafiltrate and lowers
plasma total p cresol but not IL-6 levels.
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Introduction
Cardiovascular disease (CVD) is the primary cause of morbidity
and mortality in End Stage Renal Disease (ESRD): approximately
50% of ESRD patients die because of CVD, and cardiovascular
mortality is 15–30 times higher in ESRD than in age-adjusted
general population [1,2]. This excess in morbidity and mortality
cannot be explained only by the high prevalence of the traditional
Framingham risk factors in these patients [3,4]. It seems, instead,
to be also dependent on Chronic Kidney Disease (CKD)-specific,
non-classical factors, such as inflammation [5], vascular calcifica-
tion [6], anemia and left ventricular hypertrophy [7]. A wealth of
data points to the retention of organic waste solutes as one of the
mechanisms leading to the development of these non-traditional
risk factors in CKD. In particular, a major role has been recently
attributed to p-cresol and to its metabolites. This aromatic
compound is generated in the gut through the bacterial
degradation of tyrosine and phenylalanine [8,9]. Once absorbed
from the intestinal mucosa, p-cresol is almost completely converted
in two main metabolites, p-cresylsulfate and p-cresylglucuronide
that are efficiently removed by the kidney [10]. Observational
studies showed that the metabolites of p-cresol accumulate in the
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plasma of patients affected with CKD. It was also shown that high
plasma concentrations of total p-cresol and, specifically, of its p-
cresylsulfate metabolite, are independently associated with CVD
and mortality, even after adjustment for known risk factors [10–
12]. Available data suggest that p-cresylsulfate may cause a diffuse
endothelial damage [13–15] and increase the percentage of
leucocytes displaying oxidative burst activity [16]. Therefore a
role has been posited for p-cresol and its metabolites as a factor
contributing to the systemic inflammation that is commonly
observed in dialysis patients [17,18].
In ESRD, there is also a strong association between elevated
circulating levels of markers of inflammations such as C-reactive
protein (CRP) and interleukin-6 (IL-6) and cardiovascular
morbidity and mortality, suggesting that systemic inflammation
could have a pathogenic role in CVD in these patients [19–23].
This could in part be due to the ability of circulating cytokines, like
IL-6, to exert a direct pro-aterogenic effect or to regulate the
release of acute phase reactants [24].
Combined, these data suggest that cardiovascular prognosis in
ESRD patients could be improved by decreasing the circulating
concentration of p-cresol and its metabolites and/or of IL-6.
Unfortunately, both conventional bicarbonate hemodialysis (HD)
and hemodiafiltration (HDF) may remove p-cresol only with a low
efficiency and they are unable to clear the plasma from IL-6 [25–
27]. Indeed, although the molecular weight of p-cresol and its
metabolites is very low, ranging around 100 Da, these compounds
cannot cross the dialysis membrane because they circulate in
plasma mostly bound to albumin being their free percentage less
than 1% [28]. Conversely, IL-6, also in its free form (MW
24.5 kDa), is a large, difficult to dialyze solute [29]. Moreover,
only about 30% of circulating IL-6 is free and the remaining 70%
circulates bound to its two soluble receptors, sIL-6R (MW 55 kDa)
and sgp80 (100 kDa), forming very high molecular weight
complexes [30].
Alternative dialysis strategies have been developed with the aim
of improving the efficiency of protein-bound compounds removal
from plasma. They are based either on the adsorption of these
compounds on resin cartridges [31,32], or on strategies that could
lower the binding of uremic toxins to plasma proteins [33]. One of
the most promising among the former is Hemo-Filtrate-Reinfusion
(HFR), a new dialysis technique that combines the processes of
diffusion, convection and adsorption [34]. In this double chamber
hemodiafiltration system, the UF is reinfused into the blood of the
patient after its passage through a resin cartridge that binds many
medium-high molecular weight solutes including some pro-
inflammatory cytokines [35]. No data are available on the ability
of this dialysis system to clear the blood of IL-6 and p-cresol or its
metabolites. Therefore, we designed the present study to evaluate
whether, during a single dialysis session, the HFR sorbent
cartridge may efficiently bind and remove from the UF either p-
cresol and its metabolites or IL-6 or both of them. To address this
question we measured total p-cresol and IL-6 concentrations in the
UF produced in the first filter of HFR system, before and after its
passage through the sorbent cartridge. We also evaluated whether
the pro-inflammatory activity exerted by the UF on peripheral
blood mononuclear cells (PBMC), harvested from healthy subjects
and cultured in vitro, was lowered by the passage through the
sorbent cartridge.
Patients and Methods
Patient selection and study protocol
This study was performed in 2011 in the Dialysis Unit of
Federico II University of Naples. We obtained approval by our
ethic committee ‘‘Carlo Romano’’ of the Federico II University
and written informed consent from all subjects, according to the
Helsinki declaration as revised in 1996. The protocol for this trial
and supporting TREND checklist are available as supporting
information; see Checklist S1 and Protocol S1.
Inclusion criteria were: the diagnosis of ESRD, the inclusion in
a regular three times weekly hemodialysis program and the
evidence of ongoing systemic inflammation, as stated by high-
sensitivity CRP (hsCRP) concentrations higher than 3 mg/L. We
chose to perform the study in patients with high circulating values
of hsCRP because they are expected to also have high IL-6
concentrations both in plasma and in the UF.
Exclusion criteria were: malignancies, systemic autoimmune
and/or infectious diseases, severe malnutrition or conditions
making necessary to artificially feed the patient.
Twelve patients (6 male/6 female) were recruited for the study.
Their mean age was 60.1611.5 years; mean dialysis vintage was
80639 months. Plasma high-sensitivity CRP was above the upper
normal limit in all patients (mean6 SD values: 44.01622.18 mg/l,
normal values ,3.0 mg/l).
The primary endpoint of the study was to establish whether IL-
6 and p-cresol were retained on the HFR cartridge during a single
dialysis session. To assess this point, we compared the concentra-
tions of these uremic toxins in UF entering (UFin) and UF exiting
(UFout) from the cartridge, collected 15 minutes after the start
(start-15 min) and 15 minutes before the end (end-225 min) of the
HFR session.
Secondary endpoints were: 1) to assess whether the pro-
inflammatory activity of the ultrafiltrate (UF) was lowered after
the passage through the HFR cartridge and 2) whether a single
HFR session decreased the circulating concentrations of total p-
cresol and IL-6 more efficiently than HD. To address the first
point, we compared the ability of UF samples collected at the
beginning and at the end of the HFR session to induce an
inflammatory response in peripheral blood mononuclear cells
(PBMCs) drawn from healthy subjects in vitro, as indicated by an
increase in IL-6 gene expression and release. To establish whether
HFR is more effective than HD in lowering IL-6 and p-cresol
serum concentrations, we compared the circulating levels of these
uremic toxins in blood samples collected before and after a single
session of either HFR or HD performed at different times in the
same patients.
HFR treatment
HFR was performed using a commercial HFR Supra Bellco
filter system (Mirandola, Italy). This system consists of a convective
stage, of a sorbent cartridge and of a diffusive stage (Fig. 1).
Therefore, in the HFR apparatus, the processes of convection,
diffusion and adsorption are physically separated. During HFR,
the blood first goes through the 0.7 m2 high-flux polyethersulfone
(polyphenylene) membrane of the convective stage. This highly
biocompatible membrane [36] has a sieving coefficient (i.e. the
ratio between solute concentrations in ultrafiltrate and plasma) for
albumin of 0.02 and, therefore, it generates an ultrafiltrate (UF)
containing small amounts of albumin. The UF generated in the
convective stage then goes through a sorbent cartridge containing
40 ml of a hydrophobic styrene resin (Selecta; Bellco, Mirandola,
Italy) that, because of its high porosity, has a very large adsorption
surface area (,700 m2/g). The cartridge adsorbs by hydrophobic
interaction a number of waste solutes contained in the UF that is,
thus, cleaned. Thereafter, this ‘‘regenerated’’ UF is reinfused into
the blood stream being mixed with the blood coming from the
convection stage into a chamber located at the bottom of the
convection stage before the diffusive section of the filter. The
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second filter, the diffusive stage of the HFR apparatus, contains a
1.7 m2 low-flux polyethersulfone (polyphenylene) membrane
(Figure 1). It mostly operates by diffusion and is also responsible
for the removal of excess water and patient’s weight loss.
The HFR dialysis system was controlled by a Formula Plus
monitor (Bellco, Mirandola, Italy) equipped with a software that
automatically determines the best ultrafiltration flow rate (Quf)
[37–39]. Mean blood and dialysate flows were 330620 ml/min
and 545685 ml/min, respectively. The Quf from the convective
section and the ultrafiltrate-reinfusion rate were kept at 50–60 ml/
min. Mean dialytic time was 240615 min. Weight loss, that was
obtained only in the diffusive section of the system, was
8006100 g/h.
The sterility of the tap water, of the water obtained after reverse
osmosis and of the dialysate was periodically checked by colony
forming unit (CFU) testing and by performing the limulus
amebocyte test (LAL) test (gel clot test) for endotoxin (PBI, Milan,
Italy). These tests gave negative results during the entire duration
of the study.
Control hemodialysis
Because both the convective and the diffusive stages of the HFR
apparatus can remove waste solutes, they could both contribute to
HFR effect on plasma p-cresol or IL-6. Therefore, in order to
dissect their respective roles, we also measured the changes of total
p-cresol and IL-6 plasma levels after a pure diffusive hemodialysis
session performed using only the second stage of the HFR system.
This represented an internal control for the HFR experiment and
gave an estimate of the HFR cartridge-independent effects.
Hemodialysis (HD) was performed with the same monitor (Bellco
Formula) and the same low flux (1.7 m2) polyethersulfone
membrane (Diapes, Bellco, Italy) and the same conditions
(dialysate and dialysis parameters including dialysate and blood
flow rates, weight loss and dialysis efficiency, as KT/V) of HFR.
Ultrafiltrate and blood samples
Four 60 ml UF samples were collected through specific rubber
stoppers located at the inlet and at the outlet of the sorbent
cartridge, using sterile disposable syringes (Fig. 1). Two of these
samples were collected 15 minutes after the beginning of the HFR
session (15 min-start), the first (UFin-15) before and the second
(UFout-15) after the passage through the adsorbent cartridge. The
other two samples were collected 225 min after the beginning of
the treatment (i.e. 15 minutes before its end, 225 min-end), also in
this case one before and the other after the passage through the
cartridge, (UFin-225 and UFout-225, respectively). Immediately
after collection, the UF samples were transferred in sterile
disposable polypropylene tubes (BD-Falcon, Milan, Italy), stored
in ice and transferred into 280u refrigerator where they were kept
until assayed for p-cresol and IL-6 determinations or used for the
experiments in vitro with human PBMC, as described below.
In all patients, 10 ml blood samples were collected from A-V
fistula 15 minutes before the beginning and 15 min after the end
of both the HFR and of the HD session. Sera were separated
immediately after centrifugation and stored at 220u until assayed.
Albumin concentrations both in serum and UF samples were
measured by nephelometry. p-Cresol and IL-6 serum concentra-
tions were measured using the techniques detailed in the next
paragraph, whereas high-sensitivity C-reactive protein (hsCRP)
was evaluated by a modified high-sensitivity laser nephelometry
technique (Berhing Diagnostics, GmbH, Marburg, Germany).
p-cresol assay
Total p-cresol (i.e. the sum of its free and protein-bound
fractions) was measured in serum and UF samples with HPLC, as
previously described [40,41]. Briefly, after heat-acid denaturation
of the binding proteins, p-cresol was extracted in ethyl acetate and
injected on the HPLC column. The UF samples (50 ml) were
vacuum dried and the obtained pellets were resuspended in 3 ml
saline solution before being denaturated and extracted. The
preliminary acidification of the samples was performed to release
bound p-cresol conjugates from plasma proteins, to make total
(bound + free) p-cresol-conjugates available for further HPLC
analysis. Plasma acidification also caused the hydrolysis of both p-
cresylsulphate and p-cresylglucuronide that were converted in p-
cresol. Therefore, this method mainly measured p-cresylsulfate that
represents the most prevalent form of p-cresol in plasma [10]. The
limits of quantification (LOQ) and of detection (LOD) were
Figure 1. Schematic representation of the HFR apparatus. The
figure shows the main components of the HFR Supra system (Bellco,
Mirandola, Italy) used in the study. 1-The blood of the patient is
pumped into the top filter (the convection stage). 2-In this stage of the
HFR apparatus, the blood is filtered by a high flux polyethersulfone
membrane. 3-The ultrafiltrate produced in the convection stage is
pumped by a second pump through a sorbent cartridge where
hydrophobic waste solutes are retained. The small syringes indicate the
points of the systems where rubber stopper for UF sample collection
are located. 4-The blood coming from the convection stage and the UF
coming from the cartridge are mixed in a chamber located between the
two filters 5-This ‘‘reconstituted’’ blood enters the bottom filter (the
diffusion stage) where it is undergoes dialytic treatment (both diffusion
and ultrafiltration for weight loss) with a low flux polyethersulfone
membrane. 6-The cleared blood is returned to the patient. (Modified
form an original image kindly provided by Dr. G. Palladino, Bellco,
Mirandola, Italy).
doi:10.1371/journal.pone.0095811.g001
Removal of p-Cresol and IL-6 by the HFR Sorbent Cartridge
PLOS ONE | www.plosone.org 3 April 2014 | Volume 9 | Issue 4 | e95811
0.150 ng/mL and 0.017 ng/ml, respectively. Calibration procedures
were repeated every two weeks (coefficient of variation ,0.5%).
Correction for hemoconcentration
The values of the concentrations of the two protein bound
solutes total p-cresol and IL-6 were corrected, in the samples
drawn at the end of the treatment, for the hemoconcentration that
occurs during dialysis by using the method proposed by Lesaffer et
al. with modifications [42]. Briefly, the concentrations measured in
blood samples collected at the end of the dialysis session were
multiplied by a correction factor (CF) consisting in the ratio
between total serum albumin concentration at the beginning
(Albt0) and at the end of dialysis (Albt240): CF = Albt0/Albt240.
IL-6 gene expression and release
To assess the pro-inflammatory activity of the different UF
samples, collected as described in the previous section, we
evaluated their ability to induce IL-6 gene expression and IL-6
release in cultured PBMCs.
PBMC were isolated from 12 healthy subjects with normal
hsCRP concentrations (1.1560.8 mg/l) by Ficoll-Hypaque (Flow
Laboratories, Irvine, UK) gradient density centrifugation (4006g
for 30 min). Cell viability, assessed by trypan blue dye exclusion,
was higher than 95%. PBMCs were resuspended in RPMI culture
medium (Sigma, Milano, Italy) supplemented with 1% heat-
inactivated FCS (Sigma) and antibiotics (penicillin and streptomy-
cin) at a density of 16106/ml, subdivided in three different
aliquots in plastic culture tubes (BD-Falcon, Milan, Italy) and
cultured for 24 h at 37uC in a 5% CO2 saturated humidity
incubator after the addition of 20% v/v NaCl (0.9%) to the first
aliquot, 20% v/v UFin-15 to the second aliquot and 20% v/v
UFout-225 to the third. At the end of the 24 incubation period, cell-
free supernatants were collected by centrifugation and stored at
280uC until assayed for IL-6 levels whereas the cell pellets were
lysed with Trizol reagent (Life Technologies, Grand Island, NY)
for total RNA extraction, as described elsewhere [30]). The
concentration and the purity of RNA were evaluated by
measuring the absorbance at 260 nm and by calculating the ratio
of absorbance at 260–280 nm using a UV spectrophotometer
(DU-800 spectrophotometer; Beckman Instruments). Five micro-
grams of total RNA were retro-transcribed and Real-Time
quantitative PCR analysis was performed with an ABI prism
7500 (Applied Biosystems, Foster City, CA) apparatus and the
TaqMan system using primers specific for IL-6 mRNA and b-
actin (sequence reported in Table 1). IL-6 mRNA levels were
normalized to those of b-actin and converted into fold changes
based on the doubling of PCR product in each PCR cycle
according to the manufacturer’s guidelines, as previously described
[43].
Statistical analysis
Data are expressed as mean 6 standard deviation. They were
analyzed using SPSS 12.0 (SPSS Inc, Chicago, IL) setting the
threshold for statistical significance at p values ,0.05. The
Shapiro-Wilk test was performed to assess whether the different
sets of data were normally distributed or not. To evaluate percent
decrease of IL-6 and total p-cresol plasma concentrations we
calculated their reduction ratios according to the formula RR =
(Cbefore-Cafter)/Cbefore, where Cbefore and Cafter indicate the sera
concentrations in blood samples collected 15 min before and 15
after either the HFR or the HD session. Statistical comparisons of
two group variables were performed using Student’s t-test for
normally distributed data and Mann-Whitney test for not-
normally distributed data. Multiple group comparisons were
performed with one way repeated measure ANOVA followed by
the Student-Newman-Keuls post hoc test.
Results
IL-6, p-cresol and albumin concentrations in UF samples
We found measurable concentrations of both total p-cresol and
IL-6 in UFin-15 that is produced by the ultrafiltration of plasma
through the polyethersulfone membrane of the first stage
convection filter. In UFin-15, the concentration of p-cresol was
about 30 times lower (0.3960.2 vs 11.666.3 mg/l) and that of IL-
6 was 5.6 times lower than in plasma (10.30610.2 vs
57.6658.3 pg/ml) (Tables 2 & 3). To assess whether a significant
amount of albumin crossed the polyethersulfone membrane of the
convection filter, we measured this protein in the UFin-15. The
concentration that we found ranged around 1/40th of plasma
values (0.160.03 vs 3.660.2 g/dl) in agreement with the value of
0.02 of albumin sieving reported by the manufacturer of these
dialysis membranes. Intriguingly, these albumin concentration
values are consistent with the hypothesis that most of the filtered p-
cresol actually crosses the dialysis membrane as protein-bound
forms. Conversely, the percent values of IL-6 concentration was
close to that of free IL-6 in plasma suggesting that only free IL-6
could cross the dialysis membrane.
To establish whether p-cresol and IL-6 in the UFin could be
adsorbed by the sorbent cartridge of the HFR system we
compared the concentrations of these uremic toxins in UFin and
UFout. As reported in Table 2, in samples collected 15 min after
the beginning of the HFR session both total p-cresol and IL-6
concentrations were significantly lower in UFout than in UFin. Also
albumin concentration was lower in UFout than in UFin (Table 2).
These findings suggested that the sorbent cartridge could retain p-
cresol, IL-6 and a small amount of albumin. To assess whether the
ability of the cartridge to adsorb these substances was maintained
till the end of the HFR session, we also measured their
concentrations in UFin-225 and UFout-225. Total cresol concen-
tration in UFin-225 was lower than in UFin-15, and it was further
lowered by the passage through the cartridge, suggesting that the
binding capacity of the cartridge was not saturated. In keeping
with this hypothesis, albumin concentration in UFin-225 was also
significantly lowered upon passage through the cartridge. Also IL-
6 concentration was significantly higher in UFin-225 than in
UFout-225. However, the concentration of this cytokine in UFin-
225 was not different from that in UFin-15 (Table 2).
Table 1. Sequence of the IL-6 and b-actin primers used in the study.
Forward Reverse Reference
IL-6 ATG AAC TCC TTC TCC ACA AGC GC GAA GAG CCC TCA GGC TGG ACT G 30
b-actin CACCATGGATGATGATATCG TGGATAGCAACGTACATGG 51
doi:10.1371/journal.pone.0095811.t001
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Effect of the passage through the sorbent cartridge on
IL-6 mRNA expression and protein release induced by the
ultrafiltrate in PBMC from healthy subjects
To establish whether the passage through the HFR cartridge
could also decrease UF pro-inflammatory activity, we compared
IL-6 gene expression in PBMC from healthy subjects cultured in
the absence (Control) or in the presence of the UF collected either
at the beginning (UFin-15) or at the end of the HFR session (UFout-
225). In addition, we compared IL-6 concentrations in the culture
media obtained by the same PMBC cultures. As expected, in the
presence of UFin-15 normal PBMCs became activated and we
observed a significant increase respect to control cultures both in
IL-6 mRNA expression (15.76610.9 fold the basal expression,
p,0.02) and IL-6 concentrations in the culture medium
(1850.926938.43 vs 462.966307.28 pg/ml, p,0.01) (Fig. 2). In
PBMCs exposed to UFout-225 IL-6 mRNA levels were signifi-
cantly higher than in control cultures but significantly lower than
in cultures treated with UFin-15 (4.1063.99 fold the basal
expression, p,0.05). Similarly, IL-6 release was higher than in
controls but lower than in PBMCs incubated withUFin-15
(462.966307.28 vs 908.56623.59 pg/ml p,0.05) (Fig. 2).
Effect of HFR and HD on plasma of IL-6 and total p-cresol
To assess whether the HFR session could also modify the
circulating levels of either total p-cresol or IL-6, we compared the
plasma concentrations of these uremic toxins in blood samples
collected from the AV fistula 15 min before the beginning and
15 min after the end of the HFR. Because a significant
hemoconcentration occurred during the dialysis, as expected
[39] and as indicated by the higher albumin concentration at the
end of HFR than at its beginning (Table 3), total p-cresol and IL-6
concentrations were corrected for this factor (see the methods
section for details). Total p-cresol plasma concentration was
significantly lower after HFR than before, whereas IL-6 level did
not change (Table 2). To evaluate whether HFR was more
effective than HD in lowering total p-cresol plasma concentra-
tions, we also measured the concentrations of this toxin in blood
samples collected in the same patients before and after a standard
HD session. Total p-cresol reduction ratio was significantly higher
after HFR than after HD (53.6612.5% vs 37.1620.2%, n = 12;
p,0.05 at Student’s t-test for paired data) (Table 3). Conversely,
even after HD, IL-6 concentrations were not significantly modified
by the treatment (Table 2).
Discussion
Because uremic protein-bound toxins are suspected to have a
role in worsening the cardiovascular prognosis in patients on
dialysis, there is a growing interest in developing therapeutic
strategies more effective than those currently available in removing
these compounds. In the present study we explored whether the
HFR Supra dialysis system could have a role in this context.
Specifically, we reported evidence that its sorbent cartridge
removed both IL-6 and p-cresol and its metabolites from the UF
and significantly lowered the UF pro-inflammatory activity in
vitro. Parallel to these effects, we observed a significantly stronger
decrease in circulating levels of total cresol, but not of IL-6, after
HFR than after HD.
Schematically the HFR apparatus may be considered as
composed by two different systems both taking part to waste
removal. The first one is a convective stage that operates an
Table 2. Albumin, total-cresol and IL-6 concentrations in ultrafiltrate samples collected before and after the HFR sorbent cartridge
at the beginning and at the end of the dialysis session.
15 min Pre-cartridge 15 min Post-cartridge 225 min Pre-cartridge 225 min Post-cartridge
Albumin (g/dl) 0.160.03 0.0860.02* 0.0960.01 0.0760.01{
Total-Cresol (mg/l) 0.3960.2 0.1460.09* 0.2560.09* 0.0460.03*
IL-6 (pg/ml) 10.30610.2 0* 11.68611.15 0.9161.01*
The data shown in the Table are the mean 6 standard deviation of albumin, total cresol and IL-6 measured in samples of the UF collected before and after being
adsorbed by the sorbent cartridge of the convection stage of the HFR Supra apparatus. Note the very low concentrations of albumin in pre-sorbent UF samples that is
consistent with the low sieving coefficient (about 0.02 for albumin) of the polyphenylene membrane of the system. The values of total cresol concentration shown are
the sum of p-cresol and p-cresol metabolite concentrations because, as we detail in the methods section, the acidic extraction method that we used converts all
p-cresol derivatives in p-cresol.
*p,0.05 vs 15 min pre-cartridge and {p,0.05 vs 225 min pre-cartridge, at repeated measure ANOVA followed by the Student-Newman-Keuls post-hoc test.
doi:10.1371/journal.pone.0095811.t002
Table 3. Serum albumin, and plasma total cresol and Il-6 concentrations before and after either HFR or HD.
Before HFR After HFR Reduction Ratio (%) Before HD After HD Reduction Ratio (%)
Albumin (g/dl) 3.660.2 4.260.3 - 3.860.3 4.260.2 -
Total Cresol (mg/l) 11.666.3 5.862.7* 53.6612.5 8.665.3 5.463.0I 37.1620.2u
IL-6 (pg/ml) 57.6658.3 48.4653.1 4.3634.5 48.7633.6 53.9648.3 -
The Table reports the mean 6 standard deviation of the values of serum albumin, plasma total cresol and IL-6 concentrations obtained in the same 12 ESRD patients
before and after two different dialysis sessions performed with standard bicarbonate hemodialysis (HD) or with HFR supra, as indicated. The Table also reports the
Reduction Ratio of p-cresol and IL-6 obtained with both HFR and HD. As described in the legend to Table 2, total cresol concentration is the sum of the concentration of
p-cresol and of its metabolites. The post-dialysis data shown in the table have been corrected for hemoconcentration as reported in the Methods section.
*p,0.005 vs preHFR,
Ip,0.005 vs preHD at Mann-Whitney test;
up,0.05 vs RR HFR at Student’s t test for paired data.
doi:10.1371/journal.pone.0095811.t003
Removal of p-Cresol and IL-6 by the HFR Sorbent Cartridge
PLOS ONE | www.plosone.org 5 April 2014 | Volume 9 | Issue 4 | e95811
ultrafiltration process and is coupled with a sorbent cartridge. The
second is a diffusive stage essentially similar to conventional HD.
As far as the first stage of HFR is concerned, the only mechanism
that contributes to the removal of toxins and waste compounds is
binding and retention on the HFR cartridge. The UF generated
by blood ultrafiltration at this HFR stage is, indeed, entirely
reinfused in patient’s general circulation after being passed
through the sorbent cartridge. Therefore, all the compounds that
are not sequestered into the cartridge are actually returned to
patient’s blood. The results of our study are consistent with the
hypothesis that both IL-6 and p-cresol and its derivatives were
actually adsorbed by the HFR cartridge in our patients. This is
mainly indicated by the evidence that the concentrations in the UF
of these uremic toxins were significantly lowered after the passage
through the cartridge. The hypothesis that the sorbent cartridge
could bind and retain IL-6 and/or p-cresol and its metabolites is
consistent with the chemical-physical characteristics of its styrene
resin that can establish strong non-covalent interactions with
hydrophobic molecules and with albumin [35].
A relevant question arises about the forms in which either p-
cresol or IL-6 bind to the resin. Both these molecules circulate,
indeed, in the plasma both as protein-bound and as free forms.
Specifically, p-Cresol and its derivatives are more than 90% bound
to albumin whereas almost 70% of IL-6 circulates as a very high
molecular complex with its soluble receptors (sIL-6R and sgp130)
[30,44]. The filtering membrane of the convection stage of the
HFR Supra apparatus (Fig. 1) has a low but measurable
permeability to albumin with an albumin sieving coefficient of
0.02. Therefore, it lets an amount of albumin ranging around
1/40th of its plasma concentration cross the membrane and appear
into the UF. This implies that uremic toxins, like p-cresol, can be
transferred in the UF also in their protein bound forms. In
addition, the free forms of p-cresol and of its metabolites are small
enough to freely permeate through the convection stage filter.
Therefore, both protein-bound and free p-cresol presumably
passed through the dialysis membrane into the UF and become
available for binding to the cartridge. Conversely, because of the
very high molecular weight of its complex with soluble IL-6
receptors, it is likely that IL-6 passed into the UF only as a free
molecule. This is consistent with the evidence that IL-6
concentration in the UF averaged 1/5th of the plasma concentra-
tion, the value expected for free IL-6 (MW 24.5 kDa) crossing
through a membrane with IL-6 sieving coefficient of about 0.3.
The evidence that we found low or undetectable IL-6 concentra-
tions in the effluent from the cartridge suggests that the IL-6 that
crossed the dialysis membrane of the first HFR stage to move into
the UF was virtually all retained by the cartridge itself. In keeping
with this result is the evidence that the ability of the UF incubation
to trigger IL-6 gene expression and release in PBMC from healthy
subjects was greatly reduced after its passage through the HFR
cartridge sorbent bed.
While the evidence discussed above suggests that HFR cartridge
contributed to clear the plasma of our patients from uremic toxins,
a role could have been played also by the second, diffusive stage of
the HFR apparatus [26]. As mentioned above, this portion of the
HFR system operates as a conventional HD system in which
diffusion represents the main mechanism of solute removal.
However, the removal of p-cresol by this mechanism is expected to
be small (regarding only its free form) and that of IL-6 null.
Indeed, less than 1% of total p-cresol circulates as free form
whereas free IL-6 is still too large to cross the low flux membrane
of the second HFR stage. As a whole these considerations suggest
that a significant amount of p-cresol and all of IL-6 removal
actually took place in the first HFR stage. This can probably
account for the significantly higher decrease of plasma p-cresol
level that we observed in our patients when they underwent HFR
as compared to HD (53.6% vs 37.1%). Interestingly, similar values
of percent decrease in plasma p-cresol concentration after HD
were recently reported by Meert et al. [45]. Therefore, our data
suggest that HFR could perform better than HD in p-cresol
removal though this conclusion remains to be confirmed in larger
studies specifically designed to address this point. Finally,
regarding classical hemodiafiltration (HDF), a previous work
showed that total p-cresol concentration decreases by 40% after
Figure 2. Effect of UFin-15 and UFout-225 on IL-6 gene
expression and on IL-6 release in PBMC cultures from healthy
subjects. A Mean 6 SD of the fold increase in IL-6 gene expression
respect to controls observed in PBMC cultures from 12 healthy
volunteers, exposed to UFin-15 (black) and UFout-225 (dark gray). Data
were normalized to b-actin mRNA expression and expressed as percent
increase respect to those obtained in control cultures, set at 1, in which
no UF was added. B, Mean6 SD of immunoreactive IL-6 concentrations
in culture media of PBMCs from twelve healthy volunteers after a 24 h
incubation with saline (basal condition, white), UFin-15 (black), or and
UFout-225 (dark gray). *p,0.05vs control; up,0.05 vscontrol and UFin-
15, at Kruskal-Wallis one way analysis of variance on ranks followed by
Student-Newman-Keuls post hoc test.
doi:10.1371/journal.pone.0095811.g002
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post-dilution and 42% after pre-dilution HDF [46] but no
comparative study with HFR has ever been performed.
Although the HFR cartridge retained IL-6, we did not observe
any significant change in serum concentrations of this cytokine
when we compared blood samples collected before and following a
single HFR session. This finding could be explained considering
that the actual amount of IL-6 removed during a single HFR is
presumably small. Based on concentration in UF and on the value
of Quf in the HFR system, we estimated that less than 10% of
circulating IL-6 could be removed by the cartridge. Remarkably,
no additional IL-6 removal can occur in the diffusive stage of the
HFR apparatus because free IL-6 cannot be dialyzed by the low
flux membrane of its filter. It is likely that the small amount of IL-6
removed by HFR could be entirely replaced either by the new
synthesis of this cytokine or by its release from tissues. It has been
suggested, indeed, that in inflamed patients, circulating IL-6
remains high despite its very short plasma half-life because it is
produced at a very high rate [27]. Under this respect we should
consider that all our patients showed a remarkable systemic
inflammation as demonstrated by the high serum concentrations
of hsCRP. It should be emphasized at this point, however, that
such a marked systemic inflammation is not the most typical
finding in ESRD patients that, instead, usually present only a
moderate inflammatory state known as ‘‘microinflammation’’
[47]. We can speculate, thus, that HFR that was ineffective against
the high IL-6 concentration of our markedly inflamed patients
could perform better in the average ESRD patient with
microinflammation.
Our findings suggest that HFR does not differ from other
dialysis systems that have all been shown ineffective in lowering
the circulating levels of IL-6 and/or of other cytokines. Specifi-
cally, IL-6 levels did not change after a single HD session, as
shown by Tarakc¸iog˘lu et al. [27] and as also observed by us in the
present paper. In addition, continuous hemofiltration was also
ineffective in lowering circulating IL-6 levels in patients with
systemic inflammatory response syndrome [48]. After measuring
the very small amounts of several cytokines such as TNFa and IL-
1 that are removed by low-volume HF (Vuf approximately 12 L/
day), Van Bommel et al. [49] estimated that a UF volumes of at
least 50 L/day should be needed to clear the plasma from these
molecules using hemofiltration.
While a single HFR session seems to be ineffective in decreasing
plasma IL-6, a substantial lowering of the circulating level of this
cytokine has been reported with repeated HFR treatment.
Specifically, Panichi et al. [29] showed that IL-6 plasma
concentration significantly decreased respect to baseline after 4
months of repeated HFR treatment. This evidence suggests that
longer follow up of HFR treatments could slowly decrease plasma
IL-6 levels by inducing a decrease in systemic inflammation. A
significant decrease of oxidative stress was also reported by Calo` et
al in patients receiving HFR [50].
In conclusion, our data provided the proof of concept that the
HFR system could represent a new method to remove p-cresol and
IL-6 from the blood. It would be interesting to evaluate whether
HFR efficiency could be increased by the new generation of
membranes with a tenfold higher sieving coefficient for albumin
(0.2) that are becoming available. These new HFR systems are
expected to greatly increase the amount of albumin bound p-cresol
and, presumably, of other inflammatory mediators that can be
retained by the cartridge and, therefore, to further increase their
advantages respect to HD in protein bound solutes removal.
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